Nanobiotix Files 6-K for Managerial Transactions
Ticker: NBTX · Form: 6-K · Filed: Dec 1, 2025 · CIK: 1760854
Sentiment: neutral
Topics: insider-transaction, disclosure, management
TL;DR
NANO files 6-K: execs making moves, watch for insider activity.
AI Summary
On December 1, 2025, Nanobiotix S.A. filed a Form 6-K to disclose transactions by persons discharging managerial responsibilities. This filing serves as a notification and public disclosure of these transactions for the company.
Why It Matters
This filing provides transparency into the trading activities of Nanobiotix's key executives and management, which can offer insights into their confidence in the company's performance.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of managerial transactions and does not contain information that inherently increases risk.
Key Players & Entities
- Nanobiotix S.A. (company) — Registrant
- December 1, 2025 (date) — Filing date and reporting period
FAQ
What is the purpose of this Form 6-K filing by Nanobiotix S.A.?
The Form 6-K is filed to provide notification and public disclosure of transactions by persons discharging managerial responsibilities.
When was this Form 6-K filed?
This Form 6-K was filed on December 1, 2025.
What type of transactions are being disclosed in this filing?
The filing discloses transactions by persons discharging managerial responsibilities.
What is the Commission File Number for Nanobiotix S.A.'s filing?
The Commission File Number is 001-39777.
Where is Nanobiotix S.A. located?
Nanobiotix S.A. is located at 60 rue de Wattignies, 75012 Paris, France.
Filing Stats: 181 words · 1 min read · ~1 pages · Grade level 12.2 · Accepted 2025-12-01 16:54:49
Filing Documents
- a6-kformmanagerstransactio.htm (6-K) — 11KB
- exhibit991december1st.htm (EX-99.1) — 4KB
- exhibit991december1st001.jpg (GRAPHIC) — 132KB
- exhibit991december1st002.jpg (GRAPHIC) — 84KB
- 0001628280-25-054480.txt ( ) — 313KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NANOBIOTIX S.A. Date December 1, 2025 By Laurent Levy, Chairman of the Executive Board 3